WO2024078288A1 - 一种抗rcp抗体及其制备方法 - Google Patents

一种抗rcp抗体及其制备方法 Download PDF

Info

Publication number
WO2024078288A1
WO2024078288A1 PCT/CN2023/120276 CN2023120276W WO2024078288A1 WO 2024078288 A1 WO2024078288 A1 WO 2024078288A1 CN 2023120276 W CN2023120276 W CN 2023120276W WO 2024078288 A1 WO2024078288 A1 WO 2024078288A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
rcp
heavy chain
light chain
seq
Prior art date
Application number
PCT/CN2023/120276
Other languages
English (en)
French (fr)
Inventor
叶俊娜
周卓超
游懿君
孙悦
王凡
杨程德
Original Assignee
上海交通大学医学院附属瑞金医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海交通大学医学院附属瑞金医院 filed Critical 上海交通大学医学院附属瑞金医院
Publication of WO2024078288A1 publication Critical patent/WO2024078288A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Definitions

  • the present invention belongs to the technical field of antibodies, and in particular relates to an anti-RCP antibody and a preparation method thereof.
  • SLE Systemic lupus erythematosus
  • SLE is an autoimmune disease, and the study of autoantibodies is of great significance in revealing its pathogenesis.
  • Evidence from clinical studies has revealed that the appearance of many autoantibodies can precede the onset of the disease.
  • Literature reports that before the diagnosis of SLE disease, or even 5 years before the first symptoms of SLE, a variety of autoantibodies can be detected in the patient's serum, such as anti-nuclear antibodies, anti-double-stranded DNA antibodies, and anti-Sm antibodies. So far, hundreds of autoantibodies have been detected in SLE patients, most of which are helpful for disease diagnosis.
  • Some autoantibodies are pathogenic and related to lupus nephritis, such as anti-dsDNA antibodies and anti-C1q antibodies.
  • PS phosphatidylserine
  • PE phosphatidylethanolamine
  • danger signals include nuclear antigens, DNA, RNA, etc., which activate the NF- ⁇ B pathway and inflammasomes to promote inflammation, increase the production of IL-6 and IL-1 ⁇ , and then activate T and B lymphocytes, further increasing the production of autoantibodies against these antigens.
  • the apoptosis and phagocytosis of cells in the body is an organic process that maintains the integrity and stability of tissues. The loss of control of this process can cause abnormal inflammatory reactions and increased production of autoantibodies.
  • RCP is related to the endocytic function of macrophages.
  • Rab protein is a guanosine-5'-triphosphatase (GTPase), which can transport cell fragments and decomposition products to the target compartments in the cell, thereby regulating the transport of substances in eukaryotic cells.
  • Rab11 is a member of the Rab protein family and can bind to its interacting protein (FIP), of which FIP includes two types: type 1 and type 2.
  • FIP1 type can bind to Rab11 to form Rab11FIP1, namely RCP.
  • RCP can participate in Fc ⁇ R-mediated phagocytosis, thereby participating in the phagocytic process.
  • the present invention provides an anti-RCP antibody, which is an anti-RCP antibody with biological activity and can weaken the phagocytic function of macrophages.
  • the RCP antibody of the present invention can be used to construct lupus-like mice.
  • the first aspect of the present invention provides an anti-RCP antibody, an anti-RCP antibody, wherein the anti-RCP antibody comprises a heavy chain variable region and a light chain variable region;
  • the heavy chain variable region comprises:
  • the heavy chain complementary determining region HCDR1 consists of the amino acid sequence shown in SEQ ID NO: 1,
  • a heavy chain complementary determining region HCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2,
  • a heavy chain complementary determining region HCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3;
  • the light chain variable region comprises:
  • the light chain complementary determining region LCDR1 consists of the amino acid sequence shown in SEQ ID NO:4,
  • a light chain complementary determining region LCDR2 consisting of the amino acid sequence shown in SEQ ID NO:5,
  • Light chain complementary determining region LCDR3 consisting of the amino acid sequence shown in SEQ ID NO:6.
  • a second aspect of the present invention provides an isolated nucleic acid encoding the above-mentioned antibody.
  • the third aspect of the present invention provides a vector comprising the above nucleic acid.
  • the fourth aspect of the present invention provides a host cell comprising the above-mentioned vector.
  • the second aspect of the present invention provides a nucleic acid molecule, which encodes the anti-RCP antibody sequence as described above.
  • the third aspect of the present invention provides a biological expression vector, which comprises the nucleic acid molecule described above.
  • the fourth aspect of the present invention provides a host cell, wherein the host cell comprises the biological expression vector described above.
  • a fifth aspect of the present invention provides a method for preparing an anti-RCP antibody, comprising the following steps:
  • the RCP isoform 2 protein was expressed in prokaryotes, and the expressed fusion protein RCP-ECD-His was collected and purified;
  • the purified fusion protein RCP-ECD-His was used to immunize mice;
  • RNA from B lymphocytes in the spleen of immunized mice performing reverse transcription amplification to obtain cDNA sequences, and specifically amplifying mouse light chain antibody variable region genes, light chain antibody constant region genes, heavy chain antibody variable region genes, and heavy chain antibody constant region genes;
  • the anti-RCP antibody sequence is used to construct an antibody protein expression vector, and induction expression and purification are performed to obtain the anti-RCP antibody.
  • the second aspect of the present invention provides a method for preparing the above-mentioned anti-RCP antibody, comprising the following steps:
  • the RCP isoform 2 protein was expressed in prokaryotes, and the expressed fusion protein RCP-ECD-His was collected and purified;
  • the purified fusion protein RCP-ECD-His was used to immunize mice;
  • RNA from spleen tissue of immunized mice and use it as a template to reverse into cDNA
  • the total RNA of peripheral blood lymphocytes of the immunized alpaca is obtained, and reverse transcription amplification is performed to obtain a cDNA sequence, and the mouse light chain antibody variable region gene, light chain antibody constant region gene, heavy chain antibody variable region gene, and heavy chain antibody constant region gene are specifically amplified;
  • the anti-RCP antibody sequence is used to construct an antibody protein expression vector, and induction expression and purification are performed to obtain the anti-RCP antibody.
  • the beneficial effects of the present invention are as follows: the anti-RCP antibody provided by the embodiment of the present invention has biological functions and can weaken the phagocytic function of macrophages.
  • the RCP antibody provided by the embodiment of the present invention can be used to construct lupus-like mice.
  • FIG1 is a diagram showing the results of SDS-PAGE analysis of recombinant FIP protein
  • Fig. 2 is a diagram showing the results of SDS-PAGE analysis of purified anti-RCP antibodies
  • Figure 3 shows the changes in phagocytic function of RAW264.7 after intervention of anti-RCP antibody and Isotype groups.
  • Antibody antibody, heavy chain: heavy chain (HC), light chain: light chain (LC), heavy chain variable region: heavy chain variable domain (VH), heavy chain constant region: heavy chain constant domain (CH), light chain variable region: light chain variable domain (VL), light chain constant region: light chain constant domain (CL);
  • Antibody refers to a molecule comprising at least the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain and at least CDR1, CDR2 and CDR3 of the light chain, wherein the molecule is capable of binding to an antigen.
  • the term antibody includes, but is not limited to, fragments capable of binding to an antigen, such as Fv, single-chain Fv (scFv), Fab, Fab', and (Fab')2.
  • the term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, and antibodies of various species such as mice, humans, cynomolgus monkeys, alpacas, etc.
  • CDR Complementarity determining region
  • HCDR1, HCDR2, and HCDR3 The CDRs located in the variable domain of the heavy chain of an antibody are referred to as HCDR1, HCDR2, and HCDR3, while the CDRs located in the variable domain of the light chain of an antibody are referred to as LCDR1, LCDR2, and LCDR3.
  • the present invention provides a method for preparing mouse anti-RCP antibodies, comprising the following steps:
  • Protein expression 1) Construction of transfection plasmid; 2) CHO cell transfection and screening of high-expressing stable cell lines; 3) Cell expansion and protein expression purification greater than 2 mg for animal immunization and subsequent screening; 4) SDS-PAGE identification and analysis.
  • mouse phage-displayed monoclonal antibodies 1) 1 mouse is selected, and the spleen is taken to construct a mouse phage-displayed immune antibody library; 2) RCP protein screening and ELISA screening are used, and flow cytometry is used to screen Fabs that can affect the phagocytic function of macrophages, and sequencing is performed; 3) Expression and purification of antibodies;
  • Full-length antibody expression 1) Fab antibody is preferably used to construct a mouse full-length antibody expression vector; 2) Expi-CHO cells are prepared for transfection; 3) Transfection is completed and expression is purified.
  • This embodiment provides an anti-RCP antibody, wherein the anti-RCP antibody comprises a heavy chain variable region and a light chain variable region;
  • the heavy chain variable region comprises:
  • the heavy chain complementary determining region HCDR1 consists of the amino acid sequence shown in SEQ ID NO: 1,
  • a heavy chain complementary determining region HCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2,
  • a heavy chain complementary determining region HCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3;
  • the light chain variable region comprises:
  • the light chain complementary determining region LCDR1 consists of the amino acid sequence shown in SEQ ID NO:4,
  • a light chain complementary determining region LCDR2 consisting of the amino acid sequence shown in SEQ ID NO:5,
  • the light chain complementary determining region LCDR3 consists of the amino acid sequence shown in SEQ ID NO:6.
  • the base sequence of the light chain variable region of the anti-RCP antibody provided in this example (LC-NT) (as shown in SEQ ID NO: 7) is as follows:
  • amino acid sequence of the light chain variable region of the anti-RCP antibody provided in this example (LC-AA) (as shown in SEQ ID NO: 8) is as follows:
  • the heavy chain variable region base sequence (HC-NT) of the anti-RCP antibody provided in this example (as shown in SEQ ID NO: 9) is as follows:
  • the heavy chain variable region base sequence (HC-AA) of the anti-RCP antibody provided in this example (as shown in SEQ ID NO: 10) is as follows:
  • the anti-RCP antibody was constructed by the following method:
  • RCP extracellular segment of RCP, RCP isoform2-ECD
  • RCP isoform2-ECD The extracellular segment of RCP, RCP isoform2-ECD
  • affinity purification was performed, and the obtained protein sample was then tested for purity and concentration by SDS-PAGE. Only when the antigen purity reached more than 95% and the antigen and antibody showed good binding could it be used for subsequent animal immunization and antibody screening.
  • Plasmid preparation process synthesize the full-length gene according to the fusion 6*his and RCP isoform2-ECD gene sequences, introduce double restriction site sequences at the upstream and downstream during synthesis to obtain gene fragments, purify and recover the target fragments on 2% agarose gel, and clone them into the pcDNA3.4 expression vector treated with the same restriction enzymes after double restriction enzyme digestion with EcoRI:G/AATTC and HindIII:A/AGCTT, transform Escherichia coli, screen the monoclonal strains, extract the plasmids for sequencing verification, and the plasmids with accurate verification (consistent with the original sequence after sequencing) are used for the next step of transfection of ExpiCHO-S cells;
  • the density of ExpiCHO-S cells (purchased from Thermo Fisher, CatNo. A29127) was 7 ⁇ 10 6 to 1 ⁇ 10 7 viable cells/mL, and the cell viability was >98%.
  • 25 mL of fresh ExpiCHO expression medium preheated at 37°C was used to adjust the cells to a final concentration of 6 ⁇ 10 6 cells/mL.
  • the prepared plasmid (25 ⁇ g in total) was diluted with 1 mL of OptiPRO SFM precooled at 4°C, and 80 ⁇ L of ExpiFectamine CHO was diluted with 920 ⁇ L of OptiPRO SFM.
  • the cell expression supernatant was centrifuged at high speed (15000g, 10min), and the resulting His-tagged protein expression supernatant was affinity purified by Ni Smart Beads 6FF (Changzhou Tiandi Renhe Biotechnology Co., Ltd., SA036050), and then the target protein was eluted with a gradient concentration of imidazole buffer. Finally, the resulting protein was replaced into PBS buffer through a concentration tube (Millipore, UFC901096).
  • the RCP-ECD-His with qualified purity was used for mouse immunization.
  • the specific operation is as follows:
  • C57BL/6 mice purchased from Shanghai Lingchang Biotechnology Co., Ltd.
  • 6-8 weeks old, female were purchased.
  • Multiple subcutaneous immunization was used for immunization.
  • the first immunization was injected with 100 ⁇ g of antigen, and the second to fourth immunizations were injected with 50 ⁇ g of antigen each time.
  • Immunization was performed once every two weeks for a total of four times. After four immunizations, the immune titer was determined by ELISA, and the ELISA antigen plate was RCP-ECD-His. The results showed that the immune titer reached 1:600000. At this time, 100 ⁇ g RCP-ECD-His was used for booster immunization. After 2 to 3 days, the spleen was taken and spleen B lymphocytes were isolated for the subsequent construction of immune antibody library.
  • B lymphocytes in the spleen of the immunized mouse obtained in step 1 above were separated, and their RNA was extracted and reverse transcribed into cDNA using a reverse transcription kit (TaKaRa, 6210A).
  • a series of primers were designed to amplify the variable regions of the light chain and heavy chain and the first constant region, and the M13 phage GIII protein was fused to the C-terminus of the heavy chain CH1, and constructed on a phage display vector.
  • the immune library finally constructed was displayed on the coat protein of the M13 phage in the form of Fab.
  • V genes of all light and heavy chains in mice and the first constant region gene degenerate primers containing NcoI and AscI, SfiI and NotI restriction sites were designed respectively, and segments containing variable and constant regions were obtained by PCR.
  • the target antibody gene fragment was inserted into the phage display vector by double enzyme digestion and ligation reaction, wherein the GIII gene was fused to the C-terminus of the heavy chain part of Fab.
  • the ligation product was recovered by a recovery kit (Omega, D6492-02), and then transformed into competent Escherichia coli SS320 cells (Lucigen, MC1061F) by an electroporator (BioRad, MicroPulser), and after 1 hour of recovery, it was coated on a 2-YT solid plate with ampicillin resistance (prepared by 1.5% tryptone, 1% yeast extract, 0.5% NaCl, 1.5% agar, mass/volume (g/mL)).
  • ampicillin resistance prepared by 1.5% tryptone, 1% yeast extract, 0.5% NaCl, 1.5% agar, mass/volume (g/mL)
  • 1 ⁇ L of bacterial solution was diluted and then plated on a plate for culture. The total number of clones formed by all electroporation products was calculated, i.e., the library capacity.
  • the library capacity of this immune library was 1 ⁇ 10 9 cfu.
  • OD 1 OD is 5 ⁇ 10 8 cfu
  • the culture was placed at 37°C and 220rpm to the logarithmic growth phase, and then VSCM13 helper phage (purchased from Stratagene) was added at a quantity 50 times the number of bacteria (i.e., the multiplicity of infection MOI was 50), mixed thoroughly, and after standing for 30 minutes, the culture was continued in a shaker at 220rpm for 1 hour.
  • the culture was centrifuged at 10,000rpm for 5 minutes, the supernatant was discarded, and the culture medium was replaced with 2-YT medium with carbenicillin/kanamycin dual resistance, and the culture was continued overnight at 30°C and 220rpm.
  • the bacterial solution was centrifuged at 13000g for 10 min, and the supernatant was collected and added with 20% PEG/NaCl (prepared with PEG 6000 with a volume concentration of 20% and 2.5M NaCl) to make the final concentration of PEG/NaCl 4%.
  • the mixture was mixed and placed on ice for 1 hour, and then centrifuged at 13000g for 10 min.
  • the precipitated phages corresponding to the mouse immune library were washed with PBS and stored for subsequent phage screening.
  • the antibodies against RCP were screened by immunotube solid phase screening.
  • the specific method is as follows:
  • 0.8 mL of 0.05% EDTA trypsin digestion solution was used to elute the phages that specifically bind to the target antigen, and then it was infected with SS320 bacteria (Lucigen, 60512-1) in the logarithmic phase, and then allowed to stand at 37°C for 30 minutes, and then cultured at 220rpm for 1 hour, and then VSCM13 helper phage was added, and allowed to stand for 30 minutes, and then cultured at 220rpm for 1 hour. Centrifuged and replaced with C+/K+2-YT medium, and continued to culture overnight at 30°C and 220rpm.
  • phages on the second day were used for the second round of screening, and so on.
  • the antigen concentrations of the second and third screenings were 5 ⁇ g/mL and 1 ⁇ g/mL, respectively.
  • the intensity of PBS washing was gradually increased, and the number of PBS elutions was 12 and 16 times, respectively.
  • 10 clones were randomly selected for sequence analysis in each round. After two or three rounds of screening, when the enrichment was obvious and the sequence showed high polymorphism, the bacteria in this round were selected for monoclonal coating preparation.
  • the supernatant of the monoclonal induced Fab induced by 0.1mM IPTG was subjected to ELISA, and the positive clones were selected for sequencing analysis. The experiment found that more than 60 positive clones with different sequences were obtained in this immune library screening.
  • the Fab prepared by these clones was further incubated with RAW264.7 cells for 1 hour.
  • the human T cell line Jurkat cells were induced with staurosporine (purchased from Biotechnology) to become apoptotic cells. After being stained with green fluorescence with PHrodo (purchased from life technology), RAW264.7 was phagocytosed, and the phagocytic function was detected by flow cytometry.
  • the Fab with the most obvious decrease in phagocytic function is the target Fab.
  • the Fab segment constructed above was connected to mouse IgG1Fc.
  • the expression and subsequent purification were carried out using the ExpiCHO transient expression system (Thermo Fisher, A29133). The specific method can be found in 1.
  • the obtained antibody was replaced into PBS buffer using an ultrafiltration concentration tube (Millipore, UFC901096). The concentration was measured using an ultra-micro spectrophotometer (Hangzhou Aosheng Instrument Co., Ltd., Nano-300). The measured A280 value was divided by the theoretical extinction coefficient of the antibody as the antibody concentration value for subsequent research, and the antibody was packaged and stored at -80°C.
  • Anti-RCP antibodies can affect macrophage phagocytosis
  • Anti-RCP antibody was incubated with RAW264.7 cells for 1 hour.
  • human T cell line Jurkat cells were induced with staurosporine (purchased from Biotech) to become apoptotic cells, stained with PHrodo (purchased from Life Technology) for 20 minutes, stained with green fluorescence, and then allowed to phagocytize by RAW264.7 for 30 minutes, and the phagocytic function of macrophages was detected by flow cytometry.
  • the results showed that compared with the Isotype group, The anti-RCP antibody reduces the phagocytic function of macrophages, that is, the anti-RCP antibody provided in the present invention has biological function.
  • the Isotype group was purchased from BBI company, model number is Mouse IgG BBI D110503-0010.
  • the left side shows the expression of anti-RCP antibodies under non-reducing (NR) conditions
  • the right side shows the expression under reducing (R) conditions.
  • anti-RCP antibody can reduce the phagocytic function of mouse macrophages, and the anti-RCP antibody prepared in the present invention can affect the phagocytic function of macrophages.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明公开了一种抗RCP抗体及其制备方法，所述抗RCP抗体包含重链可变区和轻链可变区；所述重链可变区包含：由SEQ ID NO:1所示的氨基酸序列组成的重链互补决定区HCDR1，由SEQ ID NO:2所示的氨基酸序列组成的重链互补决定区HCDR2，由SEQ ID NO:3所示的氨基酸序列组成的重链互补决定区HCDR3；所述轻链可变区包含：由SEQ ID NO:4所示的氨基酸序列组成的轻链互补决定区LCDR1，由SEQ ID NO:5所示的氨基酸序列组成的轻链互补决定区LCDR2，由SEQ ID NO:6所示的氨基酸序列组成的轻链互补决定区LCDR3。本发明提供的抗RCP抗体，具有生物学功能，可以减弱巨噬细胞吞噬功能，本发明中的RCP抗体可用于构建狼疮样小鼠。

Description

一种抗RCP抗体及其制备方法 技术领域
本发明属于抗体技术领域，具体涉及一种抗RCP抗体及其制备方法。
背景技术
系统性红斑狼疮(systemic lupus erythematosus，SLE)是以多系统及器官损伤并伴随大量自身抗体产生为特征的全身性自身免疫性疾病。本病在我国患病人数高达910万，多发于青年女性，病情进展快，如得不到控制可很快进展为多器官衰竭，5年生存率仅为73％，是危害人类生命的主要死亡疾病之一。
SLE作为自身免疫性疾病，自身抗体的研究对揭示其发病机制具有重要意义。临床研究的证据揭示，许多自身抗体的出现可早于疾病的发生，文献报道在SLE疾病的诊断之前、甚至在SLE首发症状之前5年，患者血清中即可检测出多种自身抗体，如抗核抗体、抗双链DNA抗体、抗Sm抗体等。至今在SLE患者中已检测到上百种自身抗体，多数自身抗体有助于疾病诊断，一些自身抗体具致病性并和狼疮肾炎相关，如抗dsDNA抗体和抗C1q抗体等。
SLE患者中细胞凋亡增多，凋亡细胞可以通过MAPK(包括JNK、p38及ERK1/2)信号通路，影响巨噬细胞的吞噬功能。正常情况下，凋亡细胞能被巨噬细胞及时清除以保持平衡。否则，积聚的凋亡细胞会引起炎症及自身免疫反应。早期凋亡细胞可表达“被清除”信号，如磷脂酰丝氨酸(PS)、磷脂酰乙醇胺(PE)等。当凋亡细胞清除受损时，多余的凋亡细胞会发生继发性凋亡，并且释放危险信号来损害免疫系统。这些危险信号包括了核抗原、DNA、RNA等，从而激活NF-κB通路及炎症小体来促进炎症，促使IL-6及IL-1β的产生增加，继而激活T、B淋巴细胞，进一步使针对这些抗原的自身抗体产生增加。
体内细胞的凋亡及吞噬处理是一个有机的过程，维持着组织的完整与稳定。这个过程的失控可以引起异常的炎症反应与自身抗体的产生增多。RCP与巨噬细胞的内吞功能相关。Rab蛋白为鸟苷-5'-三磷酸酶(GTPase)，能将细胞碎片及分解产物运输到细胞内目标小室去，从而调控真核细胞内物质的运输。Rab11为Rab蛋白家族中的一员，能与其相互作用蛋白(FIP)相结合，其中FIP包括两种类型：1型与2型。FIP1型能与Rab11相结合，形成Rab11FIP1，即RCP。RCP可以参与FcγR介导的吞噬作用，从而参与吞噬过程。
现有小鼠抗RCP抗体不具有生物学功能，无法产生影响巨噬细胞吞噬功能的作用。
发明内容
本发明提供了一种抗RCP抗体，为具有生物活性的抗RCP抗体，可以减弱巨噬细胞吞噬功能，本发明中的RCP抗体可用于构建狼疮样小鼠。
本发明第一方面提供了一种抗RCP抗体，一种抗RCP抗体，所述抗RCP抗体包含重链可变区和轻链可变区；
所述重链可变区包含：
由SEQ ID NO:1所示的氨基酸序列组成的重链互补决定区HCDR1，
由SEQ ID NO:2所示的氨基酸序列组成的重链互补决定区HCDR2，
由SEQ ID NO:3所示的氨基酸序列组成的重链互补决定区HCDR3；
所述轻链可变区包含：
由SEQ ID NO:4所示的氨基酸序列组成的轻链互补决定区LCDR1，
由SEQ ID NO:5所示的氨基酸序列组成的轻链互补决定区LCDR2，
由SEQ ID NO:6所示的氨基酸序列组成的轻链互补决定区LCDR3。
本发明第二方面提供了一种编码如上述抗体的分离的核酸。
本发明第三方面提供了一种包含上述核酸的载体。
本发明第四方面提供了一种包含上述载体的宿主细胞。
本发明第二方面提供了一种核酸分子，所述的核酸分子编码如上所述的抗RCP抗体序列。
本发明第三方面提供了一种生物学表达载体，所述的生物学表达载体包含如上所述的核酸分子。
本发明第四方面提供了一种宿主细胞，所述的宿主细胞包含如上所述的生物学表达载体。
本发明第五方面提供了一种抗RCP抗体的制备方法，包括以下步骤：
对RCP isoform 2蛋白进行原核表达，收集表达的融和蛋白RCP-ECD-His并纯化；
将纯化后的融和蛋白RCP-ECD-His用于免疫小鼠；
获取免疫小鼠的脾脏中的B淋巴细胞的总RNA，并进行反转录扩增得到cDNA序列，特异性扩增小鼠轻链抗体可变区基因、轻链抗体恒定区基因、重链抗体可变区基因、重链抗体恒定区基因；
将所述小鼠轻链抗体可变区基因、轻链抗体恒定区基因、重链抗体可变区基因、重链抗体恒定区基因与载体连接得到连接产物，将所述连接产物进行转化构建噬菌体展示文库；
从所述噬菌体展示文库淘选获得抗RCP抗体序列；
利用所述抗RCP抗体序列构建抗体蛋白表达载体，并进行诱导表达和纯化，得到抗RCP抗体。
本发明第二方面提供了一种上述抗RCP抗体的制备方法，包括以下步骤：
对RCP isoform 2蛋白进行原核表达，收集表达的融和蛋白RCP-ECD-His并纯化；
将纯化后的融和蛋白RCP-ECD-His免疫小鼠；
获取免疫小鼠脾脏组织的RNA，以其为模板反转成cDNA
获取免疫羊驼的外周血淋巴细胞的总RNA，并进行反转录扩增得到cDNA序列，特异性扩增小鼠轻链抗体可变区基因、轻链抗体恒定区基因、重链抗体可变区基因、重链抗体恒定区基因；
将所述小鼠轻链抗体可变区基因、轻链抗体恒定区基因、重链抗体可变区基因、重链抗体恒定区基因与载体连接得到连接产物，将所述连接产物进行转化构建噬菌体展示文库；
从所述噬菌体展示文库淘选获得抗RCP抗体序列；
利用所述抗RCP抗体序列构建抗体蛋白表达载体，并进行诱导表达和纯化，得到抗RCP抗体。
与现有技术相比，本发明的有益效果如下：本发明实施例提供的抗RCP抗体具有生物学功能，可以减弱巨噬细胞吞噬功能，本发明实施例提供的RCP抗体可用于构建狼疮样小鼠。
说明书附图
图1为重组FIP蛋白的SDS-PAGE鉴定分析结果图；
图2为纯化抗RCP抗体的SDS-PAGE分析结果图；
图3为抗RCP抗体和Isotype组干预RAW264.7后吞噬功能的变化结果图。
具体实施方式
在本文中，由「一数值至另一数值」表示的范围，是一种避免在说明书中一一列举该范围中的所有数值的概要性表示方式。因此，某一特定数值范围的记载，涵盖该数值范围内的任意数值以及由该数值范围内的任意数值界定出的较小数值范围，如同在说明书中明文写出该任意数值和该较小数值范围一样。
在本申请中，除非另有说明，“或”的使用意味着“和/或”。在多个从属权利要求的情况下，仅仅在替代方案中使用“或”引用一个以上的前述独立或从属权利要求。
除非另外指明，正如根据本公开所使用的，以下术语应理解为具有以下含义：
需要说明的是，本发明中所使用的科学和技术术语及其缩略语具有本领 域技术人员通常理解的含义。以下列举了本发明中使用的部分术语和缩略语：
抗体：antibody，重链：heavy chain(HC)，轻链：light chain(LC)，重链可变区：heavy chain variable domain(VH)，重链恒定区：heavy chain constant domain(CH)，轻链可变区：light chain variable domain(VL)，轻链恒定区：light chain constant domain(CL)；
“抗体”是指至少包含重链的互补决定区CDR1、CDR2和CDR3并且至少包含轻链的CDR1、CDR2和CDR3的分子，其中该分子能够与抗原结合。抗体这一术语包括但不限于能够结合抗原的片段，例如Fv，单链Fv(scFv)、Fab、Fab’、和(Fab’)2。术语抗体还包括但不限于嵌合抗体、人源化抗体和各种物种如小鼠、人、食蟹猴、羊驼等的抗体。
“互补决定区”或“CDR”是抗体可变结构域中在序列上高变并且形成在结构上确定的环(“超变环”)和/或含有抗原接触残基(“抗原接触点”)的区域。CDR主要负责与抗原表位结合。重链和轻链的CDR通常被称作CDR1、CDR2和CDR3，从N-端开始顺序编号。位于抗体重链可变结构域内的CDR被称作HCDR1、HCDR2和HCDR3，而位于抗体轻链可变结构域内的CDR被称作LCDR1、LCDR2和LCDR3。
本发明提供了一种小鼠抗RCP抗体的制备方法，包括以下步骤：
1、基因合成与载体构建：1)合成RCP isoform 2蛋白(645aa)全长基因序列；2)将基因构建入带有His标签的真核表达载体。
2、蛋白表达：1)构建转染质粒；2)CHO细胞转染，高表达稳定细胞株筛选；3)细胞扩培、蛋白表达纯化大于2mg，用于动物免疫和后期筛选；4)SDS-PAGE鉴定分析。
3、小鼠免疫：1)RCP蛋白免疫3只小鼠，免疫4次；2)免疫结束取血清小样，检测效价；
4、鼠源噬菌体展示单抗制备：1)优选1只小鼠，取脾脏构建小鼠源噬菌体展示免疫抗体库；2)用RCP蛋白海选、ELISA筛选，并用流式细胞术筛选能影响巨噬细胞吞噬功能的Fab，测序；3)表达纯化抗体；
5、全长抗体表达：1)优选Fab抗体构建小鼠源全长抗体表达载体；2)Expi-CHO细胞准备转染；3)完成转染，表达纯化。
下面结合具体实施例，进一步阐述本发明。应该理解，这些实施例仅用于说明本发明，而不用于限定本发明的保护范围。在实际应用中本领域技术人员根据本发明做出的改进和调整，仍属于本发明的保护范围。
实施例
本实施例提供了一种抗RCP抗体，所述抗RCP抗体包含重链可变区和轻链可变区；
所述重链可变区，其包含：
由SEQ ID NO:1所示的氨基酸序列组成的重链互补决定区HCDR1，
由SEQ ID NO:2所示的氨基酸序列组成的重链互补决定区HCDR2，
由SEQ ID NO:3所示的氨基酸序列组成的重链互补决定区HCDR3；
所述轻链可变区，其包含：
由SEQ ID NO:4所示的氨基酸序列组成的轻链互补决定区LCDR1，
由SEQ ID NO:5所示的氨基酸序列组成的轻链互补决定区LCDR2，
由SEQ ID NO:6所示的氨基酸序列组成的轻链互补决定区LCDR3。
本实施例提供的抗RCP抗体的轻链可变区碱基序列(LC-NT)(如SEQ ID NO:7所示)如下：

本实施例提供的抗RCP抗体的轻链可变区氨基酸序列(LC-AA)(如SEQ ID NO:8所示)如下：
本实施例提供的抗RCP抗体的重链可变区碱基序列(HC-NT)(如SEQ ID NO:9所示)如下：

本实施例提供的抗RCP抗体的重链可变区碱基序列(HC-AA)(如SEQ ID NO:10所示)如下：
本实施例中上述抗RCP抗体通过以下方法构建：
1.抗原制备、鉴定和小鼠免疫
在RCP的胞外区段RCP isoform2-ECD融合6*his，通过ExpiCHO系统进行瞬转表达。表达上清离心后，进行亲和纯化，得到的蛋白样品再通过SDS-PAGE进行纯度和浓度测定，当抗原纯度达到95％以上且抗原和抗体呈现良好的结合后才能用于后续动物免疫和抗体筛选。
其中，对于抗原的瞬转表达和纯化，其具体操作如下：
质粒制备过程：根据融合6*his和RCP isoform2-ECD基因序列合成全长基因，合成时在上下游引入双酶切位点序列，获得基因片段，2％琼脂糖凝胶纯化回收目的片段，经EcoRI:G/AATTC，HindIII:A/AGCTT双酶切后分别克隆到相同酶切处理的pcDNA3.4表达载体上，转化大肠杆菌后，筛选单克隆菌株，提取质粒用于测序验证，验证准确(测序后与原序列一致)的质粒供下一步转染ExpiCHO-S细胞用；
转染当天，ExpiCHO-S细胞(购自Thermo Fisher，CatNo.A29127)密度为7×106至1×107个活细胞/mL，细胞活率>98％，此时用37℃预热的新鲜ExpiCHO表达培养基25mL将细胞调整到终浓度为6×106个细胞/mL。用4℃预冷的OptiPRO SFM 1mL稀释制备的质粒(共25μg)，同时用920μL OptiPRO SFM稀释80μL ExpiFectamine CHO，再将两者混合并轻轻吹打混匀制备成ExpiFectamine CHO/质粒DNA混合液。混合液室温孵育1-5min之后转移到准备好的细胞悬液中，缓慢加入并同时轻轻摇晃细胞悬液，最后置于细胞培养摇床中，在37℃，5％CO2条件下培养。在转染后18-22个小时内添加ExpiCHO Enhancer和ExpiCHO Feed，摇瓶放置于32℃摇床和5％CO2条件下继续培养，在转染后第5天，添加相同体积的ExpiCHO Feed，缓慢加入的同时轻轻混匀细胞混悬液。转染12-15天后，将细胞表达上清高速离心(15000g，10min)，所得His标签蛋白表达上清通过Ni Smart Beads 6FF(常州天地人和生物科技有限公司，SA036050)进行亲和纯化，然后采用梯度浓度的咪唑缓冲液洗脱目的蛋白。最后所得蛋白通过浓缩管(Millipore，UFC901096)置换至PBS缓冲液当中。
将纯度鉴定合格的RCP-ECD-His用于小鼠免疫，具体操作如下：
购买C57BL/6小鼠(购自上海灵畅生物科技有限公司)，6-8周龄，雌性。免疫时采取皮下多点免疫的方式，首次免疫注射抗原100μg，第2次至第4次每次免疫注射抗原50μg，每两星期免疫一次，共免疫四次；免疫四次后通过ELISA测定免疫的效价，其中ELISA抗原包板采用RCP-ECD-His。测定结果显示免疫效价达到1：600000，此时采用100μg RCP-ECD-His进行加强免疫，2到3天后取脾脏，分离脾脏B淋巴细胞，用于后续免疫抗体库的构建。
2.免疫抗体库构建和筛选
分离按照上述步骤1所得经免疫的小鼠脾脏中的B淋巴细胞，抽取其RNA，并通过反转录试剂盒(TaKaRa，6210A)反转录成cDNA。设计一系列的引物分别扩增轻链和重链的可变区以及第一个恒定区，并且在重链CH1的C端融合M13噬菌体GIII蛋白，构建至噬菌体展示用载体上，最终构建的免疫库以Fab的形式展示在M13噬菌体的外壳蛋白上。
其中具体操作如下：
根据小鼠中所有轻链和重链的V基因和第一个恒定区基因分别设计含有NcoI和AscI、SfiI和NotI酶切位点的简并引物，PCR得到含有可变区和恒定区的区段，通过双酶切和连接反应将目的抗体基因片段插入至噬菌体展示用载体上，其中在Fab的重链部分的C端融合了GIII基因。连接产物通过回收试剂盒(Omega，D6492-02)回收，然后通过电转仪(BioRad，MicroPulser)转化至感受态大肠杆菌SS320细胞(Lucigen，MC1061F)中，复苏1小时后，涂布于具有氨苄抗性的2-YT固体平板(由胰蛋白胨1.5％，酵母提取物1％，NaCl0.5％，琼脂1.5％，按质量/体积(g/mL)配制而成)。为了计算库容，同时将1μL菌液进行稀释，而后在平板上进行涂布培养，通过长出的克隆数目进行推算，计算将所有电转化产物形成的总克隆数，即库容容量。此免疫库的库容为1×109cfu。
基于库容容量，挑取50个OD(1个OD为5×108cfu)的以上构建的小鼠免疫库菌加入到新鲜的2-YT液体培养基中。置于37℃，220rpm培养至对数生长期，再以50倍于细菌数的数量(即感染复数MOI为50)，加入VSCM13辅助噬菌体(购自Stratagene)，充分混匀，静置30min后，在220rpm的摇床中继续培养1小时。随后，将培养物以10000rpm的转速离心5min后，弃上清，将培养液替换为羧苄青霉素/卡那霉素双抗性的2-YT培养基，并于30℃，220rpm继续培养过夜。次日，菌液于13000g离心10min，收集上清后加入20％PEG/NaCl(由体积浓度为20％的PEG 6000和2.5M NaCl配制而成)使得PEG/NaCl最终浓度为4％，混匀，并置于冰上1小时，再以13000g的转速离心10min，将沉淀得到小鼠免疫库对应的噬菌体用PBS洗后保存并用于后续噬菌体筛选。
采用免疫管固相筛选的方式筛选针对RCP的抗体，具体方法如下：
第一轮筛选时，在免疫管中加入4mL的50μg/mL的RCP-His，4℃包被过夜，第二天弃去包被液，加入含5％奶粉的PBS封闭2h，PBS洗两次后加入制备好的噬菌体(总量为1012cfu)，孵育2h。用PBS洗8遍，后用PBS-T洗2遍，以去除非特异性结合的噬菌体，然后向免疫管中加入0.8mL含0.05％ EDTA的胰酶消化液，用于洗脱特异性结合目标抗原的噬菌体，接着将其侵染对数期的SS320菌体(Lucigen，60512-1)，37℃静置30min，然后220rpm条件下培养1h，再加入VSCM13辅助噬菌体，静置30min，继续在220rpm条件下培养1h。离心并置换至C+/K+2-YT培养基中，并于30℃，220rpm环境下继续培养过夜。
第二天制备噬菌体：最终得到的噬菌体继续用于第二轮的筛选，如此反复，其中第二次和第三次筛选的抗原浓度分别5μg/mL和1μg/mL，除此之外，PBS洗强度也逐渐加大，PBS洗脱次数依次为12次和16次。同时对每轮随机挑选10个克隆进行序列分析。经过两到三轮的筛选，当富集较明显并且序列呈现较高多态性时，选择这一轮的菌进行单克隆涂布制备。通过将0.1mM IPTG诱导的单克隆诱导Fab上清进行ELISA，选择阳性克隆进行测序分析。实验发现，此次免疫库筛选得到了超过60个具有不同序列的阳性克隆。通过进一步将这些克隆制备的Fab与RAW264.7细胞进行孵育1小时。同时人T细胞系Jurkat细胞用星孢菌素(购自生工)诱导后成为凋亡细胞，用PHrodo(购自life technology)染上绿色荧光后，让RAW264.7进行吞噬后，流式检测吞噬功能。其中吞噬功能下降最明显的Fab即为目标Fab。
3.构建小鼠抗RCP抗体全长
通过以上构建的Fab段，连接上小鼠IgG1Fc。并通过ExpiCHO瞬转表达系统(Thermo Fisher，A29133)进行表达以及后续的纯化，具体方法可以参见1。最后通过超滤浓缩管(Millipore，UFC901096)将所得抗体置换至PBS缓冲液中。并通过超微量分光光度计(杭州奥盛仪器有限公司，Nano-300)进行浓度测定，将经测定的A280数值除以抗体理论消光系数后的数值作为后续研究的抗体浓度值，分装并保存于-80℃。
4.抗RCP抗体可以影响巨噬细胞吞噬功能
抗RCP抗体与RAW264.7细胞进行孵育1小时。同时人T细胞系Jurkat细胞，用星孢菌素(购自生工)诱导后成为凋亡细胞，用PHrodo(购自life technology)染20分钟，染上绿色荧光后，然后让RAW264.7对其进行吞噬30分钟后，流式细胞术检测巨噬细胞吞噬功能。结果提示，与Isotype组相比， 抗RCP抗体使巨噬细胞的吞噬功能下降，即本发明中所提供的抗RCP抗体具有生物学功能。
其中，Isotype组购自BBI公司，型号为Mouse IgG BBI D110503-0010。
由图1可知，在非还原(NR)及还原(R)条件下，均可见110kDa及75kDa条带，由于FIP蛋白内部含5个N糖基化位点，推测两条带均为目的蛋白，其分子量差异来自于糖基化修饰。
图2中，左侧为非还原(NR)，右侧为还原(R)条件下，抗RCP抗体的表达。
由图3可知，相比于Isotype(同种型)，抗RCP抗体可以使得小鼠巨噬细胞吞噬功能下降，本发明中制备所得抗RCP抗体能够影响巨噬细胞吞噬功能。
以上公开的仅为本发明优选实施例。优选实施例并没有详尽叙述所有的细节，也不限制该发明仅为所述的具体实施方式。显然，根据本说明书的内容，可作很多的修改和变化。本说明书选取并具体描述这些实施例，是为了更好地解释本发明的原理和实际应用，从而使所属领域技术人员能很好地利用本发明。本发明仅受权利要求书及其全部范围和等效物的限制。
在本发明及上述实施例的教导下，本领域技术人员很容易预见到，本发明所列举或例举的各原料或其等同替换物、各加工方法或其等同替换物都能实现本发明，以及各原料和加工方法的参数上下限取值、区间值都能实现本发明，在此不一一列举实施例。
基因序列表




Claims (5)

  1. 一种抗RCP抗体，其特征在于，所述抗RCP抗体包含重链可变区和轻链可变区；
    所述重链可变区包含：
    由SEQ ID NO:1所示的氨基酸序列组成的重链互补决定区HCDR1，
    由SEQ ID NO:2所示的氨基酸序列组成的重链互补决定区HCDR2，
    由SEQ ID NO:3所示的氨基酸序列组成的重链互补决定区HCDR3；
    所述轻链可变区包含：
    由SEQ ID NO:4所示的氨基酸序列组成的轻链互补决定区LCDR1，
    由SEQ ID NO:5所示的氨基酸序列组成的轻链互补决定区LCDR2，
    由SEQ ID NO:6所示的氨基酸序列组成的轻链互补决定区LCDR3。
  2. 一种核酸分子，其特征在于，所述的核酸分子编码权利要求1所述的抗RCP抗体序列。
  3. 一种生物学表达载体，其特征在于，所述的生物学表达载体包含权利要求2中所述的核酸分子。
  4. 一种宿主细胞，其特征在于，所述的宿主细胞包含权利要求3所述的生物学表达载体。
  5. 一种抗RCP抗体的制备方法，其特征在于，包括以下步骤：
    对RCP isoform 2蛋白进行原核表达，收集表达的融和蛋白RCP-ECD-His并纯化；
    将纯化后的融和蛋白RCP-ECD-His用于免疫小鼠；
    获取免疫小鼠的脾脏中的B淋巴细胞的总RNA，并进行反转录扩增得到cDNA序列，特异性扩增小鼠轻链抗体可变区基因、轻链抗体恒定区基因、重链抗体可变区基因、重链抗体恒定区基因；
    将所述小鼠轻链抗体可变区基因、轻链抗体恒定区基因、重链抗体可变区基因、重链抗体恒定区基因与载体连接得到连接产物，将所述连接产物进行转化构建噬菌体展示文库；
    从所述噬菌体展示文库淘选获得抗RCP抗体序列；
    利用所述抗RCP抗体序列构建抗体蛋白表达载体，并进行诱导表达和纯化，得到抗RCP抗体。
PCT/CN2023/120276 2022-10-11 2023-09-21 一种抗rcp抗体及其制备方法 WO2024078288A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211244354.1 2022-10-11
CN202211244354.1A CN116102652B (zh) 2022-10-11 2022-10-11 一种抗rcp抗体及其制备方法

Publications (1)

Publication Number Publication Date
WO2024078288A1 true WO2024078288A1 (zh) 2024-04-18

Family

ID=86266296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/120276 WO2024078288A1 (zh) 2022-10-11 2023-09-21 一种抗rcp抗体及其制备方法

Country Status (2)

Country Link
CN (1) CN116102652B (zh)
WO (1) WO2024078288A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116102652B (zh) * 2022-10-11 2024-05-31 上海交通大学医学院附属瑞金医院 一种抗rcp抗体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077526A1 (en) * 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN116102652A (zh) * 2022-10-11 2023-05-12 上海交通大学医学院附属瑞金医院 一种抗rcp抗体及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506356A (ja) * 2004-02-24 2008-03-06 アメリカ合衆国 Ｒａｂ９ａ、ｒａｂ１１ａ、および感染症に関するこれらのモジュレーター
CN110841062A (zh) * 2019-11-22 2020-02-28 中国药科大学 LMTK1及其Ser34磷酸化蛋白作为阿尔茨海默症药物靶点的用途
CN112662689B (zh) * 2020-12-31 2022-07-19 山西大学 飞蝗Rab11A基因及其dsRNA在飞蝗防治中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077526A1 (en) * 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN116102652A (zh) * 2022-10-11 2023-05-12 上海交通大学医学院附属瑞金医院 一种抗rcp抗体及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHI HIN WONG ET AL.: "CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNAlncRNA pathway and stabilizing epithelialmesenchymal transition protein", MOLECULAR CANCER, vol. 21, no. 10, 4 January 2022 (2022-01-04), XP093157882, ISSN: 1476-4598 *
JIN, M. ; GOLDENRING, J.R.: "The Rab11-FIP1/RCP gene codes for multiple protein transcripts related to the plasma membrane recycling system", BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION., ELSEVIER, AMSTERDAM., NL, vol. 1759, no. 6, 1 June 2006 (2006-06-01), NL , pages 281 - 295, XP027896517, ISSN: 0167-4781 *

Also Published As

Publication number Publication date
CN116102652B (zh) 2024-05-31
CN116102652A (zh) 2023-05-12

Similar Documents

Publication Publication Date Title
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
TWI718206B (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
TWI796328B (zh) Ｂ７-ｈ３抗體、其抗原結合片段及其醫藥用途
CN104884473B (zh) Il-17a/f il-23双特异性抗体及其应用
RU2663721C1 (ru) Моноклональные антитела к человеческому il-17 и их применение
JP2023075294A (ja) 抗ｃｄ４７抗体及びその応用
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
TW201922784A (zh) ４﹘１ｂｂ抗體及其製備方法和應用
CN114621345B (zh) 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN110144011B (zh) 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体
WO2015146438A1 (ja) ヒト上皮増殖因子受容体を標的とした二重特異性抗体
WO2024078288A1 (zh) 一种抗rcp抗体及其制备方法
WO2024046239A1 (zh) 靶向人gprc5d的重组人源化单克隆抗体及其应用
CN114262377B (zh) 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列
CN111040035A (zh) 针对il-17ra蛋白的抗体及其制备方法和应用
WO2017198148A1 (zh) 一种il-13抗体及其制备方法和应用
CN113527493A (zh) 一种b7-h3抗体及其应用
CN111051343A (zh) Il-6r抗体、其抗原结合片段及医药用途
WO2023273595A1 (zh) 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用
CN116162161A (zh) 一种抗il-6r的单域抗体及其用途
JP2024505966A (ja) Ｂｃｍａ及びｃｄ３に結合する二重特異性抗体、及びその作製方法並びにその使用
CN116234559A (zh) 抗cd22单结构域抗体和治疗性构建体
EP2851427A1 (en) Method for producing and obtaining variable domains of anti-digoxin monoclonal antibody fab fragment using the molecular biology cloning technique
WO2024040658A1 (zh) 一种抗trem2的单域抗体及其用途
CN117043192B (zh) 针对IL-13Rα2的抗体及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23876493

Country of ref document: EP

Kind code of ref document: A1